Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Eslicarbazepine Acetate Monotherapy Long Term Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00910247
Recruitment Status : Completed
First Posted : May 29, 2009
Results First Posted : July 17, 2018
Last Update Posted : July 17, 2018
Sponsor:
Information provided by (Responsible Party):
Sunovion

Brief Summary:
This is a long term, open-label, safety extension study in subjects with partial onset seizures.

Condition or disease Intervention/treatment Phase
Epilepsy Drug: Eslicarbazepine acetate Phase 3

Detailed Description:

This is a long term, multicenter, open-label, safety extension study in subjects with partial onset seizures who have just completed, discontinued, or exited the 18-week treatment phase of Protocols 093-045 or 093-046. The initial study duration is 1 year with the option of continuing study drug treatment post 1 year until a subject discontinues study, the study drug becomes clinically available in the subject's locale, or the sponsor terminates the study drug clinical development program.

This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 274 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Masking Description: open label
Primary Purpose: Treatment
Official Title: Long Term Eslicarbazepine Acetate Extension Study
Study Start Date : August 2009
Actual Primary Completion Date : April 15, 2017
Actual Study Completion Date : April 15, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Epilepsy

Arm Intervention/treatment
Experimental: eslicarbazepine acetate
Open-label treatment with eslicarbazepine acetate will be at doses between 800 and 2400 mg QD
Drug: Eslicarbazepine acetate
800 to 2400 mg once daily (QD)
Other Names:
  • SEP-0002093
  • BIA 2-093




Primary Outcome Measures :
  1. Number and Percent of Subjects With Treatment Emergent Adverse Events [ Time Frame: One year ]
    Number and percent of subjects with treatment emergent adverse events


Secondary Outcome Measures :
  1. Number and Percentage of Subjects With Potentially Clinically Significant Clinical Laboratory Evaluations [ Time Frame: 1 year ]
    Number and percentage of subjects with potentially clinically significant clinical laboratory evaluations

  2. Number and Percent of Subjects With Normal Baseline Sodium Reaching Blood Sodium ≤135 mmol/L, ≤130 mmol/L, and ≤125 mmol/L [ Time Frame: 1 year ]
    Number and percentage of subjects who had normal sodium value (i.e. >135 mEq/L) at baseline but reached <=135 mEq/L and >130 mEq/L, <=130 mEq/L and >125 mEq/L, or <=125 mEq/L at any post baseline.

  3. Percentage of Subjects With Increase of Body Weight ≥7% [ Time Frame: 1 year ]
    Percentage of subjects with increase of body weight ≥7%

  4. Number and Percentage of Subjects With Orthostatic Effects. [ Time Frame: 1 year ]
    Number and percentage of subjects with orthostatic effects.

  5. Number and Percentage of Subjects With QTc-F Changes (in Categories) From Baseline. [ Time Frame: Baseline, Month 12 ]

    Number and percentage of subjects by QT interval corrected using the Fridericia fomula (QTcF) categories

    Based on the numbers of subjects who had at least one post-baseline assessment, the number and percentage of subjects with QTcF values in the following categories were summarized:

    1. >500 millisecond (msec) at any post-baseline timepoint but not present at baseline
    2. >480 msec at any post-baseline timepoint but not present at baseline
    3. >450 msec at any post-baseline timepoint but not present at baseline
    4. Change from Baseline >=60 ms for at least one post-baseline measurement
    5. Change from Baseline >=30 ms for at least one post-baseline measurement and <60 ms for all post-baseline measurement

    QT interval is a measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle.


  6. Percentage of Events in Each Classification of the Columbia Suicide Severity Rating Scale (C SSRS). [ Time Frame: 1 year ]

    The C-SSRS is an instrument designed to systematically assess and track suicidal behavior and suicidal ideation. The C-SSRS will be completed by the Investigator or Sub-Investigator (or qualified site personnel).

    Suicidal ideation is collected as any occurrence of wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods (not plan) without intent to act, active suicidal ideation with some intent to act, without specific plan, active suicidal ideation with specific plan and intent.

    Suicidal behavior is collected as any occurrence of actual attempts, Non-Suicidal Self-Injurious Behavior, interrupted attempts, aborted attempts, or preparatory acts or behavior, suicidal behavior.

    Any suicidality is defined as having at least one occurrence of Suicidal Behavior or Suicidal Ideation.


  7. Time on Eslicarbazepine Acetate Monotherapy. [ Time Frame: One year ]
    The start of the monotherapy period was defined as the date of termination of all other anti-epileptic drugs while taking study medication. Time on eslicarbazepine acetate monotherapy is defined from the date of the first monotherapy dose in 093-045 or 093-046 study to the last known dose of monotherapy treatment, regardless of dose change and the time gap between the parent studies and the current study.

  8. Change in Seizure Frequency From Baseline. [ Time Frame: Month 12 from baseline ]
    Relative (%) change in standard seizure frequency(SSF) from baseline

  9. Responder Rate (Percentage of Subjects With a ≥50% Reduction of Seizure Frequency From Baseline). [ Time Frame: One year ]
    Responder rate (percentage of subjects with a ≥50% reduction of seizure frequency from baseline).

  10. Percentage of Subjects That Are Seizure-free During Study [ Time Frame: 1 year ]
    Percentage of subjects that are seizure-free during study

  11. Completion Rate (% of Subjects Completing the One Year Treatment) [ Time Frame: One year ]
    Completion rate (% of subjects completing the one year treatment)

  12. Treatment Retention Time (Time to Withdrawal Due to Lack of Efficacy or Adverse Events) [ Time Frame: One year ]
    The retention time is defined from the start of eslicarbazepine acetate monotherapy period in 093-045 or 093-046 to the last known dose of open-label eslicarbazepine acetate. The time may include taking eslicarbazepine acetate concomitantly with other anti-epileptic drugs. If a subject's termination reason(s) includes: withdrawal of consent, lost to follow-up, physician decision or other, then it was assumed the subject terminated the study due to lack of efficacy.

  13. Change in Total Score From Baseline in 31-Item Quality of Life in Epilepsy (QOLIE-31). [ Time Frame: baseline and Month 12 ]

    Change in the overall score from baseline in 31-Item Quality of Life in Epilepsy (QOLIE-31 )

    The QOLIE-31 overall score was obtained by using a weighted average of multi-item scale scores. The recorded responses were converted to 0-100 point scales. The mean of the individual item scores in each subgroup were calculated, with higher converted scores reflecting better quality of life.


  14. Change in Total Score From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS). [ Time Frame: 1 year ]
    The total score of MADRS is defined as the sum of all individual item scores. Each of the 10 symptoms of depression on MADRS is measured on a scale of 0 to 6 with 0 representing the lowest severity of the symptom and 6 representing the highest severity.

  15. Change in Total Score From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) in Those Subjects With a MADRS Score of ≥14 at Screening [ Time Frame: baseline and Month 12 ]
    The total score of MADRS is defined as the sum of all individual item scores . Each of the 10 symptoms of depression on MADRS is measured on a scale of 0 to 6 with 0 representing the lowest severity of the symptom and 6 representing the highest severity.

  16. Completion Rate (% of Subjects Completing Each Visit Post-one Year). [ Time Frame: post 1 year ]
    Completion rate (% of subjects completing each visit post-one year).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   16 Years to 70 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Subject Inclusion/Exclusion Criteria:

  • Subject who completed, exited, or discontinued for reasons other than safety from the 18-week treatment phase of Protocols 093-045 or 093-046 and are willing to continue participation in this study are eligible. Subject must have completed at least the first 3 weeks of the 18-week double-blind treatment period of Protocols 093-045 or 093-046 to be eligible.
  • Subject must give written informed consent prior to participation in the study. For subjects <18 years of age, the informed consent must be signed by the subject's parent or legal guardian, and, when appropriate and/or required by state or local law, minor subjects must give written informed assent prior to participation in the study. All subjects must sign privacy authorization form, if applicable. All females of child bearing potential (≤65 years of age) must also sign the "Women of Childbearing Potential" Addendum.
  • Subjects must, in the opinion of the Investigator (with consultation with Medical Monitor as appropriate), continue to potentially benefit from continued study participation and have no new medical conditions that would preclude study participation.
  • If female subject, must continue the accepted method of birth control defined in Protocols 093-045 or 093-046 for the duration of this study as well
  • Criterion for Continuation into the Post 1 year Part of Study:

For subjects to continue into the post 1 year part of the study, subjects must, in the opinion of the Investigator (with consultation with Medical Monitor, as appropriate), continue to potentially benefit from continued study participation and have no new medical conditions that would preclude study participation.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00910247


Locations
Show Show 122 study locations
Sponsors and Collaborators
Sunovion
Investigators
Layout table for investigator information
Study Director: CNS Medical Director Sunovion Pharmaceuticals
  Study Documents (Full-Text)

Documents provided by Sunovion:
Statistical Analysis Plan  [PDF] May 19, 2017
Study Protocol: Final  [PDF] June 7, 2013
Study Protocol: Amendment history  [PDF] November 15, 2013

Layout table for additonal information
Responsible Party: Sunovion
ClinicalTrials.gov Identifier: NCT00910247    
Other Study ID Numbers: 093-050
First Posted: May 29, 2009    Key Record Dates
Results First Posted: July 17, 2018
Last Update Posted: July 17, 2018
Last Verified: July 2018
Keywords provided by Sunovion:
Seizures
Epilepsy
Anticonvulsant
Monotherapy
Epilepsy with simple or complete partial onset seizures
Additional relevant MeSH terms:
Layout table for MeSH terms
Epilepsy
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Eslicarbazepine acetate
Anticonvulsants
Voltage-Gated Sodium Channel Blockers
Sodium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action